TULOBUTEROL

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C12H18ClNO
Molecular Weight	227.73
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1

InChI

InChIKey=YREYLAVBNPACJM-UHFFFAOYSA-N

InChI=1S/C12H18ClNO/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13/h4-7,11,14-15H,8H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C12H18ClNO
Molecular Weight	227.73
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078
Curator's Comment: description was created based on several sources, including: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf

Tulobuterol is a long-acting beta2-adrenergic receptor agonist. Tulobuterol has almost no effects on blood pressure and heart rate and is highly selective for the tracheal muscle. It is indicated to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and emphysema. Serious side effects detected were: tremor, palpitations and serum potassium level decrease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15212190	Agonist 2662

Conditions

Condition	Modality	Highest Phase	Product
Bronchial asthma 48 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078	Palliative	Approved 8360	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 3.68064004E11
Bronchitis 51 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078	Palliative	Approved 8360	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 3.68064004E11
Chronic obstructive pulmonary disease 173 Sources: http://hokunalin.jp/patient/introduction/effect.html	Palliative	Approved 8360	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, COPD or emphysema. Launch Date 3.68064004E11
Emphysema 13 Sources: http://www.mylan.co.jp/-/media/mylanjp/documents/epd_products/20170220%20hokunalin1ds0.1_r7.pdf	Palliative	Approved 8360	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 3.68064004E11

PubMed

Title	Date	PubMed
Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol.	1987 Dec	2893778
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital.	2001 Jan	11201164
Effects of a nitro compound patch on neuropathy in Churg-Strauss syndrome.	2003 Jul	12823139
High-performance liquid chromatography electrospray ionization mass spectrometry determination of tulobuterol in rabbit's plasma.	2005 Feb 7	15664761
The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma.	2006 Jun	16802779
Immunology and homeopathy. 3. Experimental studies on animal models.	2006 Jun	16786046
Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids.	2006 Sep	16939989
[Simultaneous determination of nine beta2-agonists residues in urines by ultra performance liquid chromatography-electrospray tandem mass spectrometry].	2007 Jul	17953220
Transdermal treatment with tulobuterol increases isometric contractile properties of diaphragm muscle in mice.	2007 Jul	17592218
Clinical efficacy of the transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophylline.	2008	18344636
Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists.	2008	17632023
Characterization of monolithic matrix patch system containing tulobuterol.	2008 Aug	18787793
Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease.	2008 Dec	18983928
Cough and transdermal long-acting beta2 agonist in Japan.	2008 Oct	18573645
Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma.	2009 Dec	19700936
Chronic eosinophilic pneumonia: a case report and review of the literature.	2009 Jul 2	19830005
Comparative study of skin permeation profiles between brand and generic tulobuterol patches.	2010	20930390
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.	2010 Apr	20155493
[Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry].	2010 Aug	21261043

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults and children aged 9 or older, apply 2 mg of the tape to the chest, back, or upper arm, once daily. For children aged 6 months to 2 years, apply 0.5 mg of the tape to the chest, back, or upper arm, once daily. For children aged 3 to 8 years, apply 1 mg of the tape to the chest, back, or upper arm, once daily. This preparation contains 2 mg of the active ingredients in a piece of tape.

Route of Administration: Transdermal

In Vitro Use Guide

The binding rate of 14 C-tulobuterol hydrochloride to the serum protein (human) was 28.14 ± 1.53% in vitro (Mean ± S.E.).

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:45:31 UTC 2023` Edited by `admin` on `Wed Jul 05 22:45:31 UTC 2023`
Record UNII	591I9SU0F7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TULOBUTEROL

Official Name

English

tulobuterol [INN]

Common Name

English

Tulobuterol [WHO-DD]

Common Name

English

TULOBUTEROL [JAN]

Common Name

English

.ALPHA.-((TERT-BUTYLAMINO)METHYL)-O-CHLOROBENZYL ALCOHOL

Common Name

English

NSC-758643

Code

English

TULOBUTEROL [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C319